Boehringer Ingelheim has released its latest innovation: TwistPak, a revolutionary mixing platform. It enables swine producers to combine two vaccines, Ingelvac CircoFLEX and Ingelvac MycoFLEX, in a convenient, fast and flexible way. TwistPak will be globally available in all registered presentation sizes starting May this year.
The patented TwistPak technology incorporates a unique, hygienic interlock at the bottom of each bottle to connect two bottles with a simple twist. This action creates one single mixing chamber, which fits in all standard vaccination devices. The new TwistPak vaccine bottles, enhanced with an ergonomic design, are a result of advanced manufacturing technologies. This is why TwistPak, jointly co-created with the industrial design and product development company DESIGNquadrat, was awarded the Red Dot Design Award 2021, category product design.
Customers today expect mixing systems to provide confidence. They want to be sure that the substances are properly mixed, the mixing process is easy, hygienic, safe as well as fast. Currently, freshly mixing two vaccines requires a transfer needle. The innovative TwistPak bottle simplifies the mixing process while retaining the flexibility of using the products as a monovalent or combined vaccine.
"TwistPak revolutionizes how vaccines are mixed," says Eva Joras, global brand manager at Boehringer Ingelheim. "The mixing platform combines the best of both worlds: the unparalleled quality and efficacy of freshly mixed vaccines with the convenience of ready-to-use solutions. The new mixing platform enhances a market-leading product range: Through the flexibility of our FLEX franchise, we are empowering our customers to create the best and most appropriate vaccination protocol for the health of their herds whilst significantly improving the vaccination process."
Ingelvac CircoFLEX immunizes against the PCV2 virus, which causes porcine circovirus‐associated disease. Ingelvac MycoFLEX prevents pigs from falling ill with the porcine respiratory disease complex, caused by Mycoplasma hyopneumoniae. Both pathogens are highly prevalent in pig farming worldwide.
Boehringer Ingelheim was the first company to introduce mixable PCV2 and Mhyo swine vaccines to the market in 2009. The company's aim was to reduce the number of injections, as they can be a source of stress for piglets. Fewer injections resulting from the mixing of vaccines increase the well-being of pigs and decrease the workload for swine producers, without compromising efficacy and safety.
The new TwistPak presentations will be first available in South Korea, followed by China and Southeast Asia. Subsequently, Boehringer Ingelheim will roll them out in more than 60 countries in order to enhance the experience of customers globally.
Source: Boehringer Ingelheim, which is solely responsible for the information provided, and wholly owns the information. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.